Huntington disease reduced penetrance alleles occur at high frequency in the general population
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To directly estimate the frequency and penetrance of CAG repeat alleles associated with Huntington disease (HD) in the general population.
Methods: CAG repeat length was evaluated in 7,315 individuals from 3 population-based cohorts from British Columbia, the United States, and Scotland. The frequency of ≥36 CAG alleles was assessed out of a total of 14,630 alleles. The general population frequency of reduced penetrance alleles (36–39 CAG) was compared to the prevalence of patients with HD with genetically confirmed 36–39 CAG from a multisource clinical ascertainment in British Columbia, Canada. The penetrance of 36–38 CAG repeat alleles for HD was estimated for individuals ≥65 years of age and compared against previously reported clinical penetrance estimates.
Results: A total of 18 of 7,315 individuals had ≥36 CAG, revealing that approximately 1 in 400 individuals from the general population have an expanded CAG repeat associated with HD (0.246%). Individuals with CAG 36–37 genotypes are the most common (36, 0.096%; 37, 0.082%; 38, 0.027%; 39, 0.000%; ≥40, 0.041%). General population CAG 36–38 penetrance rates are lower than penetrance rates extrapolated from clinical cohorts.
Conclusion: HD alleles with a CAG repeat length of 36–38 occur at high frequency in the general population. The infrequent diagnosis of HD at this CAG length is likely due to low penetrance. Another important contributing factor may be reduced ascertainment of HD in those of older age.
GLOSSARY
- CI=
- confidence interval;
- CPMC=
- Coriell Personalized Medicine Collaborative;
- HD=
- Huntington disease;
- IRB=
- institutional review board;
- UBC C&W CREB=
- University of British Columbia Children's and Women's Health Centre Clinical Research Ethics Board
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Editorial, page 247
- Received September 15, 2015.
- Accepted in final form March 16, 2016.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Author Response Re: Huntington Disease: Intermediate CAG Repeats
- Michael R. Hayden, Killam Professor of Medical Genetics, University of British Columbiamrh@cmmt.ubc.ca
- Chris Kay, Vancouver, Canada
Submitted October 17, 2016 - Huntington disease: Intermediate CAG repeats
- Joseph Jankovic, Professor of Neurology, Baylor College of Medicinejosephj@bcm.edu
- F. Squitieri, MD, PhD; Rome, Italy
Submitted July 20, 2016
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Genetic testing of children at risk for Huntington's diseaseMartha A. Nance, US Huntington Disease Genetic Testing Group et al.Neurology, October 01, 1997 -
Articles
DNA analysis in hereditary dentatorubral-pallidoluysian atrophyCorrelation between CAG repeat length and phenotypic variation and the molecular basis of anticipationO. Komure, A. Sano, N. Nishino et al.Neurology, January 01, 1995 -
Articles
Weight loss in Huntington disease increases with higher CAG repeat numberN. A. Aziz, J.M.M. van der Burg, G. B. Landwehrmeyer et al.Neurology, November 03, 2008 -
Brief Communication
Diagnosis of patients presenting to a Huntington disease (HD) clinic without a family history of HDM. A. Nance, B. Westphal, S. Nugent et al.Neurology, December 01, 1996